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Results: No statistically significant changes to the PTV dose was noted 
during treatment (p= 0.8). Dose to the parotid glands (left and right 
respectively) changed significantly between the 1st and 30th fractions 
(p=0.02 and 0.01 respectively). Percentage weight loss between RT 
was significant (P=0.01) between the 1st and 30th fraction, as was the 
difference in the TS (p=0.02). There was no statistically significant 
difference in MUAC and MAMC. A negative correlation was found 
between the changes in weight (3.5%) between pre to mid treatment, 
with that of increased parotid gland dose. This leads us to hypothesize 
that a weight loss above 3.5% in the first half of treatment could 
potentially alert clinicians of likely dose increase in the parotid 
glands, necessitating adaptive planning strategies. 
Conclusions: There is a significant increase in dose to the parotid 
glands during treatment although the dose to the PTV remains 
relatively stable. Weight loss and Triceps thickness changes were the 
two most significant clinical parameters that changed during 
radiation. A negative correlation existed between early changes of 
these clinical factors and overall parotid dose changes during 
radiotherapy. A prospective study with more patients could now be 
designed to ascertain if a threshold percentage difference in Weight 
loss and TS changes could predict a significant parotid dose change.  
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Purpose/Objective: Numerous clinical trials have demonstrated that 
the loco-regional control and disease specific survival in patients with 
HNSCC can be significantly improved by reducing the total treatment 
time by the so called 'accelerated fractionation'. Such principle has 
most recently been demonstrated and confirmed in a large 
international randomized trial conducted by the IAEA as well as by a 
recent meta-analysis. The problems of overcoming hypoxia in head 
and neck cancers have been addressed in numerous clinical trials 
using different kinds of hypoxic modification and both the experience 
from major individual controlled clinical trials as well as a meta-
analysis has shown that such modification of hypoxia results in 
significantly better local control, disease-specific and overall survival. 
Repopulation and hypoxia are independent factors, and it is thus to be 
expected that the optimal treatment option is a reduced treatment 
time using concomitant hypoxic modification. Such treatment 
principle is also applied by some institutions and collaborative groups 
(such as DAHANCA), but the true value of adding a hypoxic modifier to 
a treatment schedule with accelerated fractionation has not been 
evaluated in a controlled clinical trial. 
Materials and Methods: A stratified, randomized phase III study of 
patients with HNSCC randomizes to accelerated radiotherapy ± 
Nimorazole. Radiotherapy will be given for both arms in 6 
fractions/week for a total dose 66-70Gy in 33-35 fractions & 
Nimorazole is to be administered in doses of approximately 1.2 g/m2 
body surface, 90 minutes prior to the first daily fraction. Quality 
assurance procedures are applied to ensure consistency and validity of 
the data. Biological materials are collected from the participating 
centers for analysis for hypoxia gene expression, as well as HPV/p16 
expression. 
Results: Patient recruitment started by the first of March 2012. 6 
centers out of 9 centers started patient’s recruitment. 47 patients are 
recruited to the trial by the beginning of December 2012. Collection 
of patient data is done through online electronic forms. Each center is 
asked to submit the radiotherapy treatment documentations of the 
first 5 recruited patients. Centers that use IMRT/3DCRT planning 
techniques are asked to upload the electronic plans of the first 5 
recruited patients on a specific FTP site. All plans are reviewed 
centrally in the trial central department by the quality assurance 
coordinator. Electronic plans could be viewed using virtual planning 
software. 
Conclusions: The trial is feasible to conduct in the participating 
centers. And treatment will be given with good quality standards. 
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Purpose/Objective: Human Papilloma Virus (HPV) status has evolved 
as one of the most important prognostic factors in head and neck 
cancer. We analyzed the relative impact of HPV-status and advanced 
radiotherapy (RT) techniques on outcome.  
Materials and Methods: Between Oct 2005 and Dec 2008 74 pts 
received definitive RT for oropharingeal cancer. In 62 pts we could 
retrospectively analyze HPV status by p16 immunohistochemistry and 
molecular analysis for HPV. P16 immunohistochemistry staining was 
performed using the CINtec® Histology V-Kit for qualitative detection 
of p16 antigen on tissue section. Both nuclear and/or cytoplasmic p16-
staining were considered to be positive. For HPV molecular biology, 
DNA extraction was performed using a Qiagen Kit. Molecular analysis 
was performed by nested PCR (AB-Analitica Kit). Mean age was 63 
years (35-84) and 84,7% of pts were male. Thirty-five pts (56.5%) 
presented with stage IV disease (all M0); 17 pts (27.4%) had base of 
tongue cancer and 34 pts (54.8%) had tonsillar cancer. In 33 pts 
(53,2%) RT was associated with concomitant chemotherapy with cis-
platinum. Seventeen pts (27.4%) underwent 3D simplified RT (3D-S, 
three field treatment with a single isocenter), followed by a 
photon/electron beam junction treatment and a 3D-conformal boost 
with a dose of 50 Gy to elective lymph node areas (CTV1) and 70 Gy to 
primary tumor and positive lymph nodes (CTV2). Twenty-two pts 
(35.5%) received 3D advanced RT (3D-A, 5 or 7 field conformal 
therapy) with doses of 50 Gy to CTV1 and 70 Gy to CTV2. Twenty-
three pts (37.1%) underwent intensity modulated RT (IMRT) with 
simultaneous integrated boost (SIB) with 2 dose levels (54-66 Gy in 30 
fractions) or 3 dose levels (54-60-69 Gy in 30 fractions). 
Results: Twenty-six pts. were P16+ (43,3%), 27 pts were PCR+ (45%) 
for HPV 16 and only one for HPV 18. Only 59 pts could be evaluated 
(two patients were lost to follow up at the time of analysis). Mean 
over all follow up is 39 months (3-80). OS, DFS and loco-regional 
control (LRC) at 3 and 5 years were 57,1,%, 51,9% and 79,6% and 
50,8%, 45,4%, 77,2% respectively. Univariate analysis based on the 
Kaplan-Meyer method (SPSS software) resulted in the identification of 
the following prognostic factors:  
Significant prognostic factor 
for OS 
p Significant prognostic factor 
for DFS 
p 
Smoking (cut-off > 10 pack 
years) 
,006 Smoking (cut-off > 10 pack 
years) 
,02 
Performance status (IK cut-
off 80) 
,000 Performance status (IK cut-off 
80) 
,000 
p16-positivity  ,000 p16-positivity  ,001 
PCR-positivity for HPV  ,007 PCR-positivity for HPV  ,03 
Treatment technique ,000 Treatment technique ,02 
 
LRC of P16+ pts was not influenced by treatment technique while in 
the HPV- cohort the 3 years DFS of pts treated with 3D-S, 3D-A and 
IMRT were 45,5%, 75% and 78% respectively, though these differences 
did not reach statistical significance for the relatively small number of 
patients. 
Conclusions: New techniques seem to be more relevant in outcome of 
p16 negative pts than in p16 positive pts probably because they allow 
a better high dose coverage of the target which may be more relevant 
in these prognostically less favourable patients. Further studies must 
be performed to confirm this hypothesis.  
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